Alle Storys
Folgen
Keine Story von ARTTIC Innovation GmbH mehr verpassen.

ARTTIC Innovation GmbH

Prostate cancer: clinicians and researchers join forces

Prostate cancer: clinicians and researchers join forces
  • Bild-Infos
  • Download

Uncovering the natural history of prostate cancer

Clinicians and researchers are joining forces in a virtual studyathon to explore the natural history of prostate cancer in a large dataset of patients from across the globe. Clinicians, epidemiologists and other researchers are invited to take part. The aim is to:

  • study the clinical management of prostate cancer.
  • support clinicians and researchers with better data on the possible outcomes of different treatment options.
  • explore the potential to generate and validate more accurate prediction algorithms based on data from Europe, the USA and other parts of the globe.

Prostate cancer is a major disease affecting more than 2 million men in Europe alone, and has now become the most common cancer in men. Clinical management of this complex disease is challenging and involves difficult trade-offs, since in reality prostate cancer consists of a spectrum of diseases ranging from low-risk to very aggressive forms. Therefore, doctors and patients have to make difficult decisions on how to treat the disease and in some case on whether or not to treat the disease, which also involves risk.

Unfortunately, there is still surprisingly little data at scale on what the ‘natural history’ (progression of the disease in absence of treatment) is and how co-morbidities (other life-threatening medical conditions) influence the life expectancy of patients diagnosed with prostate cancer. It would greatly aid shared-decision making between clinicians and patients to have a better understanding of which patients will pass away as a result of prostate cancer versus other causes, to establish where treatment would be most effective and to avoid unnecessary interventions for patients.

Joint forces to study the clinical management of prostate cancer

To achieve this clinicians and researchers are joining forces in a virtual studyathon to explore the natural history of prostate cancer in a large dataset of patients from across the globe. The aim of the studyathon is to support clinicians and researchers with better data on the possible outcomes of different treatment options and to explore the potential to generate and validate more accurate prediction algorithms based on data from Europe, the USA and other parts of the globe.

New big data approaches pioneered by OHDSI and EHDEN are changing the way in which medical evidence is generated through systematic large-scale data analysis in health data sources globally. In particular, a studyathon is a focused event in which a large-scale study, which traditionally takes many months to complete, is executed and completed in a few days. This approach has recently successfully been applied to studies in rheumatoid arthritis, hypertension and COVID-19 (see links below), and we now aim to do the same for prostate cancer. Movember is supporting this project too with project design ideas drawn from their experiences in multidisciplinary, global collaboration.

Via PIONEER and EHDEN, datasets with healthcare records for more than 1 million patients with prostate cancer are already accessible for the studyathon, but we are seeking additional data sources with longitudinal data, especially those converted to the OMOP Common Data Model to join this effort. Clinicians, epidemiologists and other researchers interested in this question are also invited to take part.

The studyathon itself will be a five day virtual event on 8-12 March 2021, with sessions every day focused on literature review, phenotype definition, analytics and results interpretation, and will follow the OHDSI approach. Please register your interest via this link and join us in this journey!

PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. IMI2 receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Weitere Storys: ARTTIC Innovation GmbH
Weitere Storys: ARTTIC Innovation GmbH